COVID 19 vaccine - Oravax Medical

Alternative Names: Oral COVID-19 vaccine - Oravax Medical

Latest Information Update: 17 Oct 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Oramed Pharmaceuticals; Premas Biotech
Developer Oravax Medical
Class COVID-19 vaccines; Peptide vaccines; Protein vaccines; Virus-like particle vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

07 Oct 2022 Preliminary immunogenicity data from a phase I trial in Covid-2019 infections (Prevention) were released by OraVax Medical
29 Dec 2021 Vietnam's Ministry of Health approves advanced stage clinical trials of oral COVID-19 vaccine
29 Dec 2021 Oravax Medical enters into a marketing and purchase agreement with Tan Thanh Holdings for oral COVID-19 vaccine in Southeast Asia includes Vietnam, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore and Thailand

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com